
  
    
      
        Background_NNP
        Psoriasis_NNP is_VBZ a_DT common_JJ skin_NN disorder_NN affecting_VBG 1_CD to_TO 3_CD
        percent_NN of_IN the_DT world_NN 's_POS population_NN ._. [_NN 1_CD 2_CD ]_NN Treatment_NNP of_IN the_DT
        disease_NN results_NNS in_IN costs_NNS that_WDT range_NN between_IN 0_CD ._. 7_CD to_TO more_JJR
        than_IN 4_CD billion_CD dollars_NNS annually_RB in_IN the_DT US_NNP alone_RB [_NN 3_CD ]_NN ._. One_CD
        of_IN the_DT most_RBS cost-effective_JJ forms_NNS of_IN potential_JJ treatment_NN for_IN
        the_DT disease_NN is_VBZ the_DT use_NN of_IN antithyroid_NN thioureylenes_NNS such_JJ a_DT
        propylthiouracil_NN ._. We_PRP previously_RB reported_VBD the_DT effectiveness_NN
        of_IN thioureylene_NN treatment_NN in_IN patients_NNS with_IN plaque_NN psoriasis_NNS
        [_NN 4_CD 5_CD 6_CD 7_CD ]_NN ,_, a_DT finding_VBG since_IN confirmed_VBN by_IN others_NNS [_NN 8_CD ]_NN ._.
        The_DT mechanism_NN of_IN action_NN of_IN antithyroid_NN thioureylenes_NNS in_IN
        psoriasis_NNS remains_VBZ unclear_JJ ._. The_DT drugs_NNS have_VBP been_VBN studied_VBN with_IN
        relation_NN to_TO their_PRP$ effect_NN in_IN Graves_NNP '_POS hyperthyroidism_NN which_WDT ,_,
        like_IN psoriasis_NNS ,_, is_VBZ an_DT autoimmune_JJ disorder_NN [_NN 9_CD 10_CD 11_CD 12_CD ]_NN
        Antithyroid_NNP thioureylenes_NNS ,_, of_IN which_WDT propylthiouracil_NN ,_,
        methimazole_NN and_CC carbimazole_NN are_VBP used_VBN in_IN clinical_JJ practice_NN ,_,
        have_VBP known_VBN immunomodulatory_NN properties_NNS [_NN 13_CD 14_CD ]_NN and_CC ,_, in_IN
        the_DT case_NN of_IN psoriasis_NNS ,_, also_RB have_VBP antiproliferative_JJ effects_NNS
        as_IN demonstrated_VBN by_IN their_PRP$ ability_NN to_TO produce_VB a_DT decline_NN in_IN
        markers_NNS of_IN cellular_JJ proliferation_NN such_JJ as_IN proliferative_JJ
        cell_NN nuclear_JJ antigen_NN (_( PCNA_NNP )_) [_NN 15_CD ]_NN ._.
        Skin_NNP antigen-presenting_JJ cells_NNS (_( Langerhans_NNP cells_NNS )_) appear_VB
        to_TO play_VB an_DT important_JJ role_NN in_IN the_DT initiating_VBG events_NNS that_WDT
        lead_VBP to_TO the_DT cytokine_NN cascade_NN that_IN results_NNS in_IN keratinocyte_NN
        proliferation_NN and_CC development_NN of_IN psoriatic_JJ lesions_NNS [_NN 16_CD 17_CD
        18_CD ]_NN ._. Effective_NNP therapeutic_JJ approaches_NNS to_TO psoriasis_NNS
        treatment_NN ,_, such_JJ as_IN psoralen_NN UV-A_NNP therapy_NN (_( PUVA_NNP )_) ,_, which_WDT
        result_VBP in_IN depletion_NN of_IN APCs_NNP in_IN the_DT skin_NN [_NN 19_CD 20_CD ]_NN ,_, and_CC
        UV-B_NN [_NN 21_CD ]_NN ,_, lead_VB to_TO one_CD of_IN the_DT most_RBS sustained_VBN improvement_NN
        in_IN psoriasis_NNS ._. IL-_NNP 12_CD ,_, a_DT product_NN of_IN Langerhans_NNP cells_NNS and_CC skin_NN
        monocytes_NNS plays_VBZ a_DT pivotal_JJ role_NN in_IN T-_NNP cell_NN activation_NN that_WDT
        leads_VBZ to_TO formation_NN of_IN the_DT psoriatic_JJ plaque_NN [_NN 22_CD ]_NN ._. IL-_NNP 12_CD
        levels_NNS are_VBP also_RB significantly_RB raised_VBD in_IN patients_NNS with_IN
        Graves_NNP '_POS hyperthyroidism_NN and_CC are_VBP reduced_VBN following_VBG treatment_NN
        with_IN propylthiouracil_NN [_NN 23_CD ]_NN ._.
        CD_NNP 1_CD a_DT is_VBZ expressed_VBN in_IN differentiated_JJ antigen-presenting_JJ
        cells_NNS and_CC monocytes_NNS and_CC is_VBZ used_VBN as_IN a_DT marker_NN for_IN the_DT
        presence_NN of_IN these_DT cells_NNS in_IN the_DT skin_NN [_NN 24_CD 25_CD 26_CD ]_NN ._. The_DT CD_NNP 1_CD
        molecules_NNS are_VBP the_DT products_NNS of_IN five_CD CD_NNP 1_CD genes_NNS located_VBN on_IN
        chromosome_NN 1_CD ._. The_DT genes_NNS are_VBP closely_RB related_VBN to_TO the_DT mixed_JJ
        histocompatibilty_NN complex_JJ (_( MHC_NNP )_) genes_NNS indicating_VBG origin_NN
        from_IN a_DT common_JJ precursor_NN [_NN 27_CD ]_NN ._. CD_NNP 1_CD molecules_NNS ,_, however_RB ,_,
        have_VBP limited_JJ sequence_NN homology_NN to_TO MHC_NNP class_NN I_PRP and_CC II_NNP
        molecules_NNS ,_, and_CC unlike_IN the_DT MHC_NNP molecules_NNS are_VBP also_RB capable_JJ of_IN
        binding_JJ non-protein_JJ antigens_NNS [_NN 28_CD 29_CD ]_NN ._.
        The_DT present_JJ study_NN was_VBD performed_VBN to_TO examine_VB the_DT effect_NN of_IN
        propylthiouracil_NN treatment_NN of_IN patients_NNS with_IN plaque_NN
        psoriasis_NNS on_IN CD_NNP 1_CD a_DT expression_NN in_IN their_PRP$ psoriatic_JJ lesions_NNS in_IN
        order_NN to_TO determine_VB whether_IN this_DT form_NN of_IN therapy_NN resulted_VBD in_IN
        depletion_NN of_IN APCs_NNP from_IN affected_VBN skin_NN ,_, that_WDT could_MD account_VB
        for_IN the_DT therapeutic_JJ benefit_NN of_IN PTU_NNP in_IN this_DT disorder_NN ._.
      
      
        Methods_NNP
        
          Patients_NNS
          Six_CD patients_NNS (_( 4_CD M_NNP ,_, 2_CD F_NN )_) with_IN stable_JJ plaque_NN psoriasis_NNS
          were_VBD recruited_VBN for_IN study_NN ._. The_DT patients_NNS ranged_VBD in_IN age_NN from_IN
          21_CD to_TO 63_CD years_NNS ,_, mean_VB ±_NN SD_NNP ,_, 44_CD ±_NN 16_CD years_NNS ._. None_NN of_IN the_DT
          patients_NNS was_VBD taking_VBG any_DT form_NN of_IN topical_JJ or_CC systemic_JJ
          treatment_NN ,_, other_JJ than_IN emollients_NNS ,_, for_IN psoriasis_NNS for_IN at_IN
          least_JJS six_CD weeks_NNS prior_RB to_TO entry_NN into_IN the_DT study_NN ._. Pregnant_NNP
          women_NNS and_CC patients_NNS with_IN thyroid_NN dysfunction_NN determined_VBN by_IN
          pre-enrollment_JJ screening_NN thyroid_NN function_NN tests_NNS were_VBD
          excluded_VBN from_IN the_DT study_NN ._. The_DT Institutional_NNP Review_NNP Board_NNP
          of_IN the_DT University_NNP of_IN California_NNP ,_, Irvine_NNP ,_, approved_VBD the_DT
          study_NN ._.
        
        
          Clinical_NNP Scoring_NNP
          Clinical_NNP evaluation_NN was_VBD performed_VBN by_IN the_DT same_JJ
          dermatologist_NN (_( VSN_NNP )_) at_IN the_DT time_NN of_IN patient_NN entry_NN into_IN the_DT
          study_NN and_CC monthly_JJ intervals_NNS until_IN completion_NN of_IN the_DT
          study_NN ._. Scoring_NNP was_VBD based_VBN on_IN the_DT PASI_NNP scoring_VBG system_NN [_NN 30_CD
          ]_NN ._.
        
        
          Biopsy_NNP Samples_NNP
          Biopsy_NNP samples_NNS were_VBD taken_VBN from_IN patients_NNS at_IN the_DT start_NN
          and_CC after_IN 3_CD months_NNS of_IN PTU_NNP treatment_NN from_IN the_DT same_JJ
          psoriatic_JJ lesion_NN ._. Skin_NNP samples_NNS were_VBD obtained_VBN using_VBG a_DT 5_CD mm_NN
          punch_NN biopsy_NN under_IN aseptic_JJ conditions_NNS with_IN local_JJ
          anesthesia_NN ._. The_DT biopsies_NNS were_VBD frozen_VBN and_CC stored_VBN at_IN -_: 70_CD °_NN C_NNP
          until_IN processed_VBN ._. Indirect_JJ immunoperoxidase_NN staining_VBG was_VBD
          used_VBN to_TO identify_VB CD_NNP 1_CD a_DT ._.
        
        
          Histological_NNP Scoring_NNP
          Biopsy_NNP specimens_NNS were_VBD viewed_VBN by_IN a_DT dermatopathologist_NN
          (_( RJB_NNP )_) ._. Histological_NNP scoring_VBG was_VBD made_VBN with_IN a_DT 5_CD -_: point_NN
          scoring_VBG system_NN graded_JJ from_IN 0_CD to_TO 4_CD (_( 0_CD =_SYM normal_JJ ,_, 1_CD =_SYM
          slight_JJ ,_, 2_CD -_: moderate_JJ ,_, 3_CD =_SYM severe_JJ ,_, 4_CD =_SYM very_RB severe_JJ )_) based_VBN
          on_IN criteria_NNS noted_VBD below_IN after_IN examination_NN of_IN four_CD
          consecutive_JJ high-power_JJ fields_NNS ._. Histological_NNP scoring_VBG took_VBD
          into_IN account_NN hypogranulosis_NNS ,_, parakeratosis_NNS and_CC the_DT
          inflammatory_JJ infiltrate_VB in_IN the_DT epidermis_NNS and_CC superficial_JJ
          dermis_NNS ._. The_DT total_JJ score_NN reported_VBD was_VBD the_DT sum_NN of_IN the_DT
          individual_JJ parameters_NNS ._. Epidermal_NNP hyperplasia_NN was_VBD measured_VBN
          with_IN an_DT oculomicrometer_NN from_IN top_NN of_IN the_DT epidermis_NNS to_TO the_DT
          base_NN of_IN the_DT ridges_NNS ._.
        
        
          Laboratory_NNP Tests_NNP
          Thyroid_NNP function_NN tests_NNS were_VBD performed_VBN in_IN all_DT
          volunteers_NNS prior_RB to_TO entry_NN into_IN the_DT study_NN and_CC again_RB at_IN
          monthly_JJ intervals_NNS until_IN study_NN completion_NN at_IN twelve_CD weeks_NNS ._.
          The_DT tests_NNS consisted_VBD of_IN measurement_NN of_IN serum_NN free_JJ T_NN 
          4_CD (_( FT_NNP 
          4_LS )_) and_CC thyroid-stimulating_JJ hormone_NN
          (_( TSH_NNP )_) ._. Complete_JJ blood_NN counts_VBZ (_( CBC_NNP )_) were_VBD also_RB obtained_VBN at_IN
          the_DT same_JJ time_NN intervals_NNS ._.
        
        
          Immunoperoxidase_NNP Staining_NNP
          Tissue_NNP samples_NNS from_IN biopsy_NN specimens_NNS stored_VBD at_IN -_: 70_CD °_NN C_NNP
          were_VBD taken_VBN and_CC embedded_VBN in_IN paraffin_NN ._. 4_LS μm_NN sections_NNS were_VBD
          coated_JJ onto_IN slides_NNS and_CC allowed_VBN to_TO dry_VB overnight_JJ at_IN 55_CD °_NN C_NNP ._.
          An_DT RBC_NNP block_NN (_( 2_CD ._. 5_LS ml_NN ,_, 30_CD %_NN H_NNP 
          2_CD O_NNP 
          2_CD in_IN 100_CD ml_NN methanol_NN )_) was_VBD applied_VBN for_IN
          40_CD min_NN after_IN which_WDT the_DT slides_NNS were_VBD washed_VBN in_IN tap_VB water_NN
          until_IN clean_VB ._. Following_VBG a_DT series_NN of_IN washing_VBG with_IN PBS_NNP ,_, the_DT
          slides_NNS were_VBD washed_VBN with_IN blocking_VBG serum_NN (_( 5_CD %_NN horse_NN serum_NN )_)
          for_IN 20_CD min_NN after_IN which_WDT antibody_NN for_IN CD_NNP 1_CD a_DT (_( 1_CD :_: 100_CD dilution_NN )_)
          was_VBD applied_VBN for_IN 30_CD minutes_NNS ._. The_DT slides_NNS were_VBD washed_VBN with_IN
          PBS_NNP for_IN 5_CD min_NN after_IN which_WDT anti-mouse_JJ antibody_NN (_( 1_CD :_: 200_CD
          dilution_NN )_) was_VBD applied_VBN and_CC the_DT slides_NNS washed_VBN again_RB in_IN PBS_NNP
          for_IN 5_CD minutes_NNS ._. Tertiary_NNP antibody_NN (_( ABC_NNP kit_NN )_) was_VBD added_VBN for_IN
          30_CD min_NN and_CC the_DT slides_NNS were_VBD then_RB washed_VBN for_IN with_IN PBS_NNP ._. DAB_NNP
          was_VBD applied_VBN in_IN the_DT dark_JJ (_( 10_CD min_NN )_) ,_, the_DT slides_NNS were_VBD washed_VBN
          in_IN distilled_VBN water_NN (_( 5_CD min_NN )_) ,_, counterstained_JJ with_IN
          hematoxylin_NN ,_, washed_VBN with_IN tap_VB water_NN ,_, dehydrated_JJ and_CC
          mounted_VBD ._.
        
        
          Quantification_NNP
          Results_NNS were_VBD expressed_VBN as_IN the_DT absolute_JJ number_NN of_IN
          positive_JJ staining_VBG dendritic_JJ cells_NNS counted_VBN over_IN a_DT 1_CD mm_NN
          length_NN of_IN the_DT epidermis_NNS ._. Only_RB cells_NNS with_IN clearly_RB defined_VBN
          nuclei_NN present_JJ in_IN the_DT suprabasal_NN layers_NNS of_IN the_DT epidermis_NNS
          were_VBD counted_VBN ._.
        
        
          Statistical_NNP Analysis_NNP
          The_DT results_NNS are_VBP expressed_VBN as_IN mean_NN ±_NN SD_NNP ._. Statistical_NNP
          analysis_NN was_VBD performed_VBN using_VBG the_DT t-test_JJ for_IN paired_VBN
          observations_NNS ._. Level_NNP of_IN significance_NN was_VBD p_NN <_NN 0_CD ._. 05_CD ._.
        
      
      
        Results_NNS
        
          Clinical_NNP Response_NNP and_CC PASI_NNP Scores_NNPS
          All_DT patients_NNS showed_VBD some_DT improvement_NN in_IN their_PRP$
          psoriasis_NNS with_IN near-complete_JJ resolution_NN in_IN 4_CD patients_NNS ._.
          PASI_NNP scores_NNS declined_VBD from_IN 21_CD ._. 40_CD ±_NN 6_CD ._. 81_CD at_IN baseline_NN to_TO
          7_CD ._. 85_CD ±_NN 4_CD ._. 35_CD at_IN completion_NN of_IN the_DT study_NN (_( p_NN <_NN 0_CD ._. 004_CD )_) ._.
          Clinical_NNP improvement_NN became_VBD apparent_JJ about_IN three_CD weeks_NNS
          after_IN therapy_NN ._.
        
        
          Histological_NNP Scores_NNPS
          Histological_NNP scores_NNS also_RB declined_VBD significantly_RB from_IN
          7_CD ._. 17_CD ±_NN 2_CD ._. 78_CD at_IN baseline_NN to_TO 3_CD ._. 00_CD ±_NN 2_CD ._. 61_CD at_IN the_DT end_NN of_IN 12_CD
          weeks_NNS PTU_NNP treatment_NN (_( p_NN <_NN 002_CD )_) ._. Epidermal_NNP thickness_NN
          decreased_VBD from_IN 0_CD ._. 52_CD ±_NN 0_CD ._. 17_CD mm_NN to_TO 0_CD ._. 26_CD ±_NN 1_CD ._. 11_CD mm_NN (_( p_NN <_NN
          0_CD ._. 007_CD )_) ._.
        
        
          Serum_NNP TSH_NNP ,_, FT_NNP 4_CD and_CC CBC_NNP
          CBC_NNP remained_VBD normal_JJ (_( 7_CD ._. 85_CD ±_NN 0_CD ._. 53_CD vs_NNS ._. 8_CD ._. 05_CD ±_NN 1_CD ._. 31_CD
          cells_NNS /_NN μL_NN ,_, p_NN =_SYM ns_NNS )_) during_IN the_DT entire_JJ study_NN with_IN no_DT patient_NN
          demonstrating_VBG any_DT leucopenia_NN ._. Serum_NNP TSH_NNP concentrations_NNS
          remained_VBD within_IN the_DT euthyroid_NN range_NN with_IN no_DT patient_NN
          exhibiting_VBG clinical_JJ signs_NNS or_CC offering_NN complaints_NNS
          suggestive_JJ of_IN hypothyroidism_NN ._. Serum_NNP free_JJ thyroxine_NN (_( FT_NNP 
          4_LS )_) showed_VBD no_DT significant_JJ change_NN ._.
          Serum_NNP TSH_NNP slowed_VBD a_DT slight_JJ rise_NN in_IN some_DT patients_NNS with_IN the_DT
          group_NN as_IN a_DT whole_JJ showing_NN no_DT significant_JJ elevation_NN of_IN TSH_NNP
          (_( 1_CD ._. 72_CD ±_NN 0_CD ._. 98_CD μU_NN /_NN ml_NN vs_NNS ._. 2_CD ._. 73_CD ±_NN 1_CD ._. 43_CD μU_NN /_NN ml_NN ,_, p_NN =_SYM ns_NNS )_) ._. The_DT
          rise_NN did_VBD not_RB exceed_VB the_DT normal_JJ range_NN ,_, and_CC all_DT patients_NNS
          remained_VBD clinically_RB euthyroid_NN ._.
        
        
          Expression_NNP of_IN CD_NNP 1_CD a_DT in_IN Psoriatic_NNP Plaques_NNP
          As_IN expected_VBN ,_, CD-_NNP 1_CD a_DT with_IN characteristic_JJ stellate_NN
          profiles_NNS typical_JJ for_IN Langerhans_NNP cells_NNS were_VBD readily_RB seen_VBN
          in_IN the_DT epidermis_NNS in_IN all_DT pre-_NN and_CC post-treatment_JJ biopsy_NN
          samples_NNS ._. The_DT number_NN of_IN CD-_NNP 1_CD a_DT staining_VBG cells_NNS showed_VBD an_DT
          apparent_JJ increase_NN after_IN propylthiouracil_NN therapy_NN ._. The_DT
          number_NN of_IN such_JJ cells_NNS rose_VBD from_IN 5_CD ._. 67_CD ±_NN 4_CD ._. 08_CD pretreatment_NN
          to_TO 10_CD ._. 00_CD ±_NN 4_CD ._. 20_CD post-treatment_JJ (_( P_NN <_NN 0_CD ._. 02_CD )_) (_( Fig_NNP 1_CD ,_,
          2_LS )_) ._.
        
      
      
        Discussion_NNP
        The_DT efficacy_NN of_IN antithyroid_NN thioureylenes_NNS as_IN agents_NNS in_IN
        the_DT treatment_NN of_IN plaque_NN psoriasis_NNS is_VBZ well_RB established_VBN [_NN 4_CD 5_CD
        7_CD 8_CD ]_NN The_DT mechanism_NN of_IN action_NN of_IN these_DT agents_NNS in_IN psoriasis_NNS
        remains_VBZ unclear_JJ ._. The_DT drugs_NNS can_MD potentially_RB act_VB by_IN reducing_VBG
        the_DT cytokine_NN signals_NNS that_WDT lead_VBP to_TO keratinocyte_NN
        proliferation_NN or_CC by_IN reducing_VBG keratinocyte_NN proliferation_NN ._. A_DT
        key_JJ element_NN in_IN the_DT generation_NN of_IN the_DT cytokine_NN signals_NNS
        responsible_JJ for_IN formation_NN of_IN a_DT psoriatic_JJ plaque_NN is_VBZ the_DT skin_NN
        antigen-presenting_JJ cell_NN or_CC Langerhans_NNP cell_NN ._. Therapeutic_NNP
        modalities_NNS deplete_VB such_JJ cells_NNS ,_, that_IN often_RB lead_VB to_TO
        improvement_NN in_IN psoriasis_NNS ._. The_DT best_JJS example_NN of_IN such_JJ an_DT
        approach_NN is_VBZ treatment_NN with_IN UV-A_NNP and_CC psoralens_NNS ,_, as_RB well_RB as_IN
        UV-B_NN ,_, which_WDT result_VBP in_IN depletion_NN of_IN APCs_NNP and_CC produce_VB one_CD of_IN
        the_DT most_RBS long-lasting_JJ remissions_NNS of_IN the_DT disease_NN which_WDT might_MD
        last_VB in_IN some_DT instances_NNS for_IN as_RB long_RB as_IN 6_CD months_NNS [_NN 31_CD 32_CD ]_NN A_DT
        key_JJ antigenic_JJ marker_NN of_IN skin_NN APCs_NNP is_VBZ CD_NNP 1_CD a_DT ._. Langerhans_NNP cell_NN
        precursors_NNS arise_VBP from_IN CD_NNP 34_CD positive_JJ monocytes_NNS /_NN macrophages_NNS
        in_IN the_DT marrow_NN [_NN 33_CD 34_CD ]_NN ._. They_PRP circulate_VBP in_IN the_DT blood_NN
        before_IN localizing_VBG in_IN the_DT skin_NN ,_, primarily_RB in_IN dermal_NN
        connective_JJ tissue_NN ._. In_IN the_DT dermis_NNS ,_, the_DT Langerhans_NNP precursors_NNS
        are_VBP strongly_RB HLA-DR_NNP (_( Ia_NNP )_) positive_JJ ,_, and_CC are_VBP relatively_RB
        non-phagocytic_JJ ,_, "_'' indeterminate_JJ cells_NNS ._. "_'' CD_NNP 1_CD a_DT expression_NN is_VBZ
        not_RB pronounced_VBN in_IN the_DT precursors_NNS and_CC is_VBZ not_RB significantly_RB
        expressed_VBD until_IN the_DT cells_NNS become_VBP differentiated_JJ ._. [_NN 35_CD 36_CD 37_CD
        38_CD ]_NN Differentiated_NNP cells_NNS localize_NN to_TO the_DT midepidermis_NNS ,_,
        demonstrate_VB characteristic_JJ Birbeck_NNP granules_NNS ,_, and_CC exhibit_VB
        dendritic_JJ appendages_NNS ._. These_DT differentiated_JJ cells_NNS ,_, although_IN
        usually_RB stable_JJ ,_, sometime_RB exhibit_NN proliferative_JJ activity_NN and_CC
        increase_NN in_IN many_JJ cutaneous_JJ immune_JJ response_NN states_NNS [_NN 23_CD 39_CD
        40_CD ]_NN ._. The_DT inability_NN of_IN PTU_NNP to_TO reduce_VB CD_NNP 1_CD a_DT expression_NN in_IN
        biopsy_NN samples_NNS of_IN patients_NNS with_IN psoriasis_NNS suggests_VBZ that_IN the_DT
        mechanism_NN of_IN action_NN of_IN this_DT drug_NN is_VBZ psoriasis_NNS is_VBZ not_RB due_JJ to_TO
        any_DT effect_NN on_IN skin_NN antigen-presenting_JJ cells_NNS or_CC production_NN
        of_IN IL-_NNP 12_CD ,_, a_DT motive_NN cytokine_NN that_WDT is_VBZ responsible_JJ for_IN
        initiation_NN and_CC maintenance_NN of_IN the_DT cytokine_NN stimulatory_NN
        cascade_NN that_WDT leads_VBZ to_TO formation_NN of_IN the_DT psoriatic_JJ plaque_NN [_NN
        16_CD ]_NN ._. In_IN support_NN of_IN this_DT argument_NN is_VBZ the_DT fact_NN that_IN
        circulating_VBG IL-_NNP 12_CD did_VBD not_RB show_VB any_DT significant_JJ change_NN with_IN
        PTU_NNP treatment_NN (_( submitted_VBN )_) ._. Additional_JJ studies_NNS are_VBP being_VBG
        performed_VBN which_WDT address_VBP whether_IN PTU_NNP treatment_NN of_IN patients_NNS
        with_IN plaque_NN psoriasis_NNS leads_VBZ to_TO reduced_VBN 
        in_IN situ_NN IL-_NNP 12_CD expression_NN ,_, alters_NNS
        production_NN of_IN the_DT IL-_NNP 35_CD or_CC IL-_NNP 40_CD components_NNS of_IN the_DT IL-_NNP 70_CD
        heterodimer_NN ,_, as_RB well_RB as_IN exerts_NNS an_DT effect_NN by_IN enhancing_VBG
        apoptosis_NNS in_IN the_DT proliferated_VBN keratinocytes_NNS that_WDT make_VBP up_RP
        the_DT psoriatic_JJ plaque_NN which_WDT would_MD result_VB in_IN clinical_JJ
        improvement_NN ._.
      
      
        Competing_VBG Interests_NNP
        None_NN declared_VBD ._.
      
    
  
